Hsp90抑制剂NVP-AUY922单药及联合用药在肿瘤治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2015.03.021

Abstract

Abstract:

Heat shock protein 90(Hsp90)is a highly conserved protein which have been proved to play an important role in the development and progression of malignant transformation.As one of small molecule inhibitors that has been detected to have potent antitumor activity in a wide range of malignancies,NVP-AUY922 is a pyrazole scaffold drug with many advantages such as low toxicity and stable structure.As a result of this,NVP-AUY922 is extensively considered as a new promising kind of anti-tumor drug.This review intends to update the reader on advances made over the past four years in the clinical development of NVP-AUY922 in advanced cancers.

Key words: Hsp90 inhibitor, Tumor, TKI, NVP-AUY922

CLC Number:

R730.53

ZHANG Jiawen,CAO Jingyan,JIN Shi,YU Yan. The advances of the HSP90 inhibitor NVP-AUY922:applied alone or in combination with anti-tumor treatment[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 284-288.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2015.03.021

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2015/V29/I3/284

References

1 肖砾,陶茂萱.健康素养研究进展与展望[J].中国健康教育,2008,24(5):361-364.
2 王绯,杨永平.Hsp90抑制剂靶向治疗癌症研究进展[J].解放军医学杂志,2006,31(3):274-275.
3 Whitesell L,Lindquist SL.Hsp90 and the chaperoning of cancer [J].Nature Reviews Cancer,2005,5(10):761-772.
4 Chen MH,Chiang KC,Cheng CT,et al.Antitumor activity of the combination of an Hsp90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma [J].Oncotarget,2014,5(9):2372-2389
5 Trepel J,Mollapour M,Giaccone G,et al.Targeting the dynamic Hsp90 complex in cancer[J].Nature Reviews Cancer,2010,10(8):537-549.
6 Camidge DR,Doebele RC.Treating ALK-positive lung cancer-early successes and future challenges [J].Nat Rev Clin Oncol,2012,9(5):268-277.
7 Smith CC,Wang Q,Chin CS.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia [J].Nature,2012,485(7397):260-263.
8 Taipale M,Jarosz DF,Lindquist S.Hsp90 at the hub of protein homeostasis:emerging mechanistic insights[J].Nat Rev Mol Cell Biol,2010,11(7):515-528.
9 Solit DB,Chiosis G.Development and application of Hsp90 inhibitors [J].Drug Discovery Today,2008,13(1):38-43.
10 Cowen LE,Singh SD,Khler JR,et al.Harnessing Hsp90 function as a powerful,broadly effective therapeutic strategy for fungal infectious disease[J].Proc Natl Acad Sci USA,2009,106(8):2818-2823.
11 Lee KH,Lee JH,Han SW,et al.Antitumor activity of NVP-AUY922,a novel heat shock protein 90 inhibitor,in human gastric cancer cells is mediated through proteasomal degradation of client proteins[J].Cancer Science,2011,102(7):1388-1395.
12 Lang SA,Klein D,Moser C,et al.Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo[J].Molecular Cancer Therapeutics,2007,6(3):1123-1132.
13 Moser C,Lang SA.Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer[J].Anticancer Research,2012,32(7):2551-2561.
14 张玮芳,彭大为.进展期胃癌分子靶向治疗的研究进展[J].海南医学,2014,(9):1321-1323.
15 Sessa C,Shapiro GI,Bhalla KN,et al.First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors [J].Clinical Cancer Research,2013,19(13):3671-3680.
16 Jensen MR,Schoepfer J,Radimerski T,et al.NVP-AUY922:a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models [J].Breast Cancer Res,2008,10(2):R33.
17 Caldas-Lopes E,Cerchietti L,Ahn JH,et al.Hsp90 inhibitor PU-H71,a multimodal inhibitor of malignancy,induces complete responses in triple-negative breast cancer models [J].Proc Natl Acad Sci USA,2009,106(20):8368-8373.
18 Varticovski L.A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas[J].Nature Medicine,2009,15(12):1369-1376.
19 Garon EB,Finn RS,Hamidi H,et al.The Hsp90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth [J].Molecular Cancer Therapeutics,2013,12(6):890-900.
20 Ueno T,Tsukuda K,Toyooka S,et al.Strong anti-tumor effect of NVP-AUY922,a novel Hsp90 inhibitor,on non-small cell lung cancer[J].Lung Cancer,2012,76(1):26-31.
21 Garon EB,Moran T,Barlesi F,et al.Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated,advanced non-small cell lung cancer(NSCLC)[C].J Clin Oncol(Meeting Abstracts),2012,30(5):7543-7544.
22 Zhou Q,Zhang XC,Peng B,et al.A phase II cluster study of single agent AUY922,BYL719,INC 280,LDK378 and MEK162 in Chinese patients with advanced non-small cell lung cancer(NSCLC)[C].J Clin Oncol(Meeting Abstracts),2014,32(5):8122-8125.
23 Samuel TA,Sessa C,Britten C,et al.AUY922,a novel Hsp90 inhibitor:final results of a first-in-human study in patients with advanced solid malignancies [J].J Clin Oncol,2010,28(5):2528-2529.
24 Ku SY,Lasorsa E,Adelaiye R,et al.Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate Cancer [J].PLoS One,2014,9(7):e103680.
25 Doi T,Onozawa Y,Fuse N,et al.Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors[J].Cancer Chemotherapy and Pharmacology,2014,74(3):629-636.
26 Chen SM,Guo CL,Shi JJ,et al.Hsp90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer[J].International Journal of Cancer,2014,135(10):2462-2474.
27 Best OG,Mulligan SP.Heat shock protein-90 inhibitor,NVP-AUY922,is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype [J].Leukemia & Lymphoma,2012,53(11):2314-2320.
28 Chen MH,Lin KJ,Yang WLR,et al.Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma[J].Cancer,2013,119(2):293-303.
29 Perez CA,Velez M,Raez LE,et al.Overcoming the resistance to Crizotinib in patients with non-Small cell lung cancer harboring EML4/ALK translocation[J].Lung Cancer,2014,84(2):110-115.
30 万静华,傅振坤.抑制性协同刺激分子B7-H4在女性常见恶性肿瘤中的研究进展[J].实用肿瘤学杂志,2015,29(1):53-56.
31 Hashida S,Yamamoto H,Shien K,et al.Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors[J].Oncology Reports,2015,33(3):1499-1504.

[1]	ZHOU Suxia, XU Zhihua, GUO Shuling, FAN Ning, XU Lili. Analysis for the prevalence trend of malignant tumor incidence and mortality in cancer registration areas in Qinghai Province from 2014 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 381-387.
[2]	LIU Yang, WANG Ying, MA Xiang, SONG JiaBao, LIU DaMin, CHEN Lili. Analysis of incidence and mortality of malignant tumors among urban residents in Yingkou City,Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 400-404.
[3]	ZHANG Xuan, LI Juan, FANG Chuanfeng, TIAN Hong, LIU Jiaren. Research progress of phytochemicals in tumor immunotherapy [J]. Journal of Practical Oncology, 2025, 39(5): 428-432.
[4]	XIN Xin, XIONG Wenjing, ZHANG Chunnuan, LI Xiaojing, GAO Xue, ZHANG Yue. Lactylation modification:an emerging target in cancer therapy [J]. Journal of Practical Oncology, 2025, 39(5): 433-436.
[5]	DAI Xiaoze, MA Yuxia, LI Yuting, QI Xiaoqing, ZHU Tiancen, MU Huijuan, LIU Hui. Analysis of the incidence and mortality trends of malignant tumors among urban residents in Fuxin City,Liaoning Province from 2014 to 2020 [J]. Journal of Practical Oncology, 2025, 39(4): 278-283.
[6]	ZHU Tiancen, LI Yanxia, REN Fanghan, DAI Xiaoze, LIU Yang, MU Huijuan. Analyses for the epidemic situation of malignant tumors in cancer registration areas of Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(4): 294-300.
[7]	LI Xiaotong, MIAO Miao, HOU Kaijiong, CHEN Hong. Research progress in the impact of GATA4 on tumors [J]. Journal of Practical Oncology, 2025, 39(4): 338-342.
[8]	CAO Jingjing, ZHANG Gong. Progress in the application of electric field therapy for tumor in the treatment of glioblastoma [J]. Journal of Practical Oncology, 2025, 39(4): 353-357.
[9]	LIANG Xiaodan, GUO Haonan. Research advances on the CDC5L gene in malignant tumors [J]. Journal of Practical Oncology, 2025, 39(4): 358-362.
[10]	LI Ji, ZHANG Maorong, YANG Zhao, WEN Hongmei, WU Fuxian, LI Yuntao. Analyses for the incidence and mortality characteristics of malignant tumors in the cancer registration areas of Kunming City,Yunnan Province in 2020 and their trend from 2016 to 2020 [J]. Journal of Practical Oncology, 2025, 39(3): 169-176.
[11]	LI Dongsheng, LI Zehao, CHEN Yonggang. Application of DNA methylation risk scoring model for ferroptosis related genes in the prognosis and immune feature assessment of colon cancer [J]. Journal of Practical Oncology, 2025, 39(3): 224-234.
[12]	YE Qianni, LI Juan, WANG Falin, LIU Jiaren. Research progress on the role of phytochemicals in tumor microenvironment [J]. Journal of Practical Oncology, 2025, 39(3): 245-250.
[13]	WU Xu, DE Leheibateer, DA Lintai, SU Nite, LIU Jun. Research progress of long non-coding RNA in oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2025, 39(3): 251-255.
[14]	WEN Xiaoyan, CHEN Li. Comparative analysis of the burden of malignant tumors among the people aged 30 and above in Sichuan province in 2010 and 2020 [J]. Journal of Practical Oncology, 2025, 39(1): 1-6.
[15]	ZHENG Gaojian, YAO Xiaoni, WU Zhongze, GONG Xinyu, CHEN Wangyang, PANG Junwei. Attributing malignant tumor deaths to alcohol exposure and DALY burden in China [J]. Journal of Practical Oncology, 2024, 38(5): 295-299.

The advances of the HSP90 inhibitor NVP-AUY922:applied alone or in combination with anti-tumor treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments